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Introduction: Although enhancer of zeste homolog 2 (EZH2) has 
been associated with both non-small cell and small-cell lung cancers 
(SCLCs), current observations suggest different mechanisms of EZH2 
activation and overexpression in these lung cancer types. Globally, 
SCLC kills 200,000 people yearly. New clinical approaches for SCLC 
treatment are required to improve the poor survival rate. Given the 
therapeutic potential of EZH2 as a target, we sought to delineate the 
downstream consequences of EZH2 disruption to identify the cellular 
mechanisms by which EZH2 promotes tumorigenesis in SCLC.
Methods: We generated cells with stable expression of short hair-
pin RNA targeting EZH2 and corresponding controls (pLKO.1) 
and determined the consequences of EZH2 knockdown on the cell 
cycle and apoptosis by means of propidium iodide staining and flu-
orescence-activated cell sorting, Western blot, quantitative reverse 
transcriptase-polymerase chain reaction as well as cell viability 
assessment using methylthiazol tetrazolium assays.
Results: We discovered that EZH2 inhibition (1) increased apoptotic 
activity by up-regulating the proapoptotic factors Puma and Bad, (2) 
decreased the fraction of cells in S or G2/M phases, and (3) elevated 
p21 protein levels, implicating EZH2 in cell death and cell-cycle 
control in SCLC.
Conclusion: Our findings present evidence for the role of EZH2 in the 
regulation of cell cycle and apoptosis, providing a biological mecha-
nism to explain the tumorigenicity of EZH2 in SCLC. Our work points 
to the great potential of EZH2 as a therapeutic target in SCLC.
Key Words: Small-cell lung cancer, Enhancer of zeste homolog 2, 
Oncogene, Retinoblastoma protein, E2 promoter binding factor.
(J Thorac Oncol. 2013;8: 1102-1106)
Small-cell lung cancer (SCLC) is a deadly malignancy requiring new clinical strategies to improve patient prog-
nosis.1 We recently demonstrated that deletion of miR-101, 
which targets enhancer of zeste homolog 2 (EZH2 ), is a 
prominent subtype specific event occurring in non–small-cell 
lung cancer (NSCLC).2 However, disruption of the retinoblas-
toma protein (RB1)/E2 promoter binding factor (E2F) pathway 
is a prominent feature of SCLCs.3,4 RB1 is inactivated in more 
than 90% of cases and amplifications of E2F2 have recently 
been described5 whereas proteomic profiling has revealed up-
regulation of E2F-regulated factors including EZH2.6 These 
observations suggest distinct mechanisms of EZH2 activation 
occur in these lung cancer types. Given that (1) EZH2 activa-
tion is a major consequence of RB1/E2F pathway deregulation 
in SCLC, (2) EZH2 has recently been correlated with SCLC 
subtype of lung cancer, and (3) the biological role of EZH2 in 
SCLC has not been established, we sought to investigate the 
functional role of EZH2 in SCLC. We studied the effects of 
EZH2 knockdown on apoptosis and cell cycle to elucidate the 
role EZH2 plays in these critical processes in SCLC.
MATERIALS AND METHODS
SCLC cell lines (HTB-175, NCI-H526, HTB-171, 
HTB-119, and NCI-H524) were purchased from American 
Type Culture Collection and had RB1 or RB1/E2F disrup-
tion.4,6 RNA interference experiments were performed using 
lentiviral short hairpin RNA (shRNA) vectors targeting 
EZH2 from Open Biosystems (details at www.openbiosys-
tems.com; RHS4533-NM_152998). RNA from cultured cells 
were converted to cDNA using an ABI High Capacity cDNA 
Archive kit (Applied Biosystems [now Life Technologies Inc.], 
Burlington, Canada) and used for standard TaqMan real-time 
polymerase chain reaction (PCR) for gene expression assays: 
EZH2 (Hs00172783_m1), Bad (Hs00188930_m1), Puma 
(Hs00248075_m1), p21 (Hs00355762_m1), and hypoxanthine 
phosphoribosyltransferase 1 (HPRT1) (Hs03929098_m1). The 
3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide 
(MTT) assay (Trevigen, Gaithersburg, MD) was used to assess 
cell viability according to the manufacturer’s instructions. Cell 
cycle and apoptosis were quantified by flow cytometry after 
ethanol fixation and propidium iodide incorporation, as pre-
viously described.7 Western blot was performed as previously 
described.7 All primary antibodies were purchased from Cell 
Signaling (Whitby, Ontario, Canada): glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH) (#14C10), Pro-Apoptosis 
BCL-2 Family (Kit #9942s; Bax, Bid, Bcl-2, Bak, Bik, Bim, 
Bad, Puma), p21 (#12D1), and EZH2 (# AC22). For all assays, 
p values were calculated using the Student’s t test and a one-
tailed p value less than 0.05 was considered significant. We 
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calculated Pearson’s correlation coefficients between mRNA 
expression levels of EZH2 and p21 for 50 SCLC cell lines using 
data available from the Broad Institute Sanger Cell Line Project 
(broadinstitute.org/cgi-bin/cancer/datasets.cgi). P53 status for 
these 50 lines was available in the COSMIC database (http://
www.sanger.ac.uk/genetics/CGP/cosmic/) and in an online 
database comprising peer-reviewed literature (http://p53.free.
fr/Database/Cancer_cell_lines/SCLC.htm). Only four of the 
50 SCLC cell lines were TP53 wild type (NCI H2081, H446, 
H209, and H1522).
RESULTS
shRNA Knockdown of EZH2 Reduces 
Transcript and Protein Levels in SCLC
The involvement of EZH2 in the RB1/E2F pathway 
prompted us to study the function of EZH2 in the context of 
cell cycle and apoptosis regulation in SCLC. We assessed a 
panel of five SCLC cell lines to determine the consequence 
of EZH2 knockdown on the fate of SCLC cells. For each 
line, we generated cells with stable expression of shRNA tar-
geting EZH2 and corresponding controls (pLKO.1). EZH2 
expression levels were significantly reduced as confirmed by 
quantitative reverse transcriptase-polymerase chain reaction 
(Supplementary Figure 1, Supplemental Digital Content 1, 
http://links.lww.com/JTO/A436) and Western blot (Fig. 1).
EZH2 is Required for Viability of SCLC Cells
We first investigated the effect of EZH2 knockdown on 
SCLC cell viability using MTT assays by comparing viability 
of control and knockdown cells over 5 consecutive days. We 
observed a drastic reduction in viability in cells with EZH2 
knockdown relative to controls for each SCLC line, although 
HTB-175 was less sensitive than the others (Fig. 2; p < 0.01 in 
all cell lines except HTB-175 for which p < 0.05). HTB-171 
was especially sensitive to EZH2 repression as essentially all 
cells died, precluding us from performing any viability studies 
on this line.
Knockdown of EZH2 is Associated 
with Increased Rates of Apoptosis 
and Decreased Proliferation
Given that EZH2 repression decreased cell viability, 
we next investigated whether this effect could be mediated 
through apoptosis or cell-cycle control. We studied the effect 
of EZH2 knockdown on cell-cycle kinetics and apoptosis rates 
using propidium iodide staining as previously described.7 We 
observed an increase of apoptotic rates in all SCLC cells with 
EZH2 knockdown relative to controls (p < 0.05), although the 
magnitude of this effect was smaller in HTB-119 (Fig. 3). This 
effect on apoptosis was coupled with a decrease in the percent-
age of cells in S or G2/M phase in knockdown versus control 
cells (Supplementary Figure 2, Supplemental Digital Content 
2, http://links.lww.com/JTO/A437). All knockdown cell lines, 
with the exception of H526, showed at least twice as many 
apoptotic cells than the PLKO controls. H526 cells had a high 
endogenous level of apoptosis but apoptotic rates were still 
significantly higher in EZH2 knockdown cells. HTB-171 was 
extremely sensitive to EZH2 knockdown, and the majority of 
knocked-down cells were apoptotic at the time of collection 
(p < 0.001). Collectively, these results suggest that the reduction 
in cell viability caused by EZH2 knockdown is caused by the 
onset of apoptosis in SCLC cell lines with EZH2 inhibition.
EZH2 Represses p21 and Apoptotic Factors 
Thereby Promoting Cell Cycling in SCLC Cells
To corroborate our findings of EZH2 association with 
apoptosis and cell-cycle regulation, we analyzed by Western 
blot the proteins involved in these two processes (Fig. 1). EZH2 
knockdown caused a drastic increase in expression of the cell-
cycle inhibitor p21 in four of five cell lines. Moreover, repression 
of EZH2 increased levels of the proapoptotic factors, Bad and 
Puma, although to a lesser extent than p21. We also observed 
cleavage of Bax and Bid in HTB-171 on EZH2 knockdown 
(Fig. 1), events that are often correlated with an active stage of 
apoptosis.7 These results are concordant with the high sensitivity 
of HTB-171 cells to EZH2 knockdown. Increases of p21, Puma, 
and Bad after EZH2 knockdown were also observed at the mRNA 
level by RT-qPCR (Supplementary Figure 3, Supplemental 
Digital Content 3, http://links.lww.com/JTO/A438).
DISCUSSION
EZH2 is a Key Factor in E2F-Driven SCLC
Although EZH2 is highly expressed in a wide range of 
cancer types, overexpression is more prominent in SCLC than 
in NSCLC,6 which is consistent with the fact that RB1/E2F 
pathway disruption is more strongly associated with SCLC. 
However, the specific function of EZH2 in SCLC has not yet 
been explored. The goal of this study was to determine the 
FIGURE 1.  Knockdown of EZH2 up-regulates proapoptotic 
factors and the cell-cycle inhibitor, p21. Immunoblotting was 
used to determine the relative expression levels of p21 and 
multiple proteins of the B-cell lymphoma 2 (BCL-2) family 
involved in the activation of apoptosis in EZH2 knockdown 
and control (PLKO) small-cell lung cancer cells. GAPDH was 
used as a loading control. EZH2, enhancer of zeste homolog 
2; GAPHD, glyceraldehyde 3-phosphate dehydrogenase.
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FIGURE 2.  EZH2 knockdown reduces SCLC viability.The MTT assay was used to compare cell viability in EZH2 knockdown 
(shEZH2) and corresponding control (PLKO) SCLC cells. Assays were performed on exponentially growing cells measured over 
5 consecutive days. Results plotted are background subtracted mean ± standard deviation absorbance values for triplicate wells 
of a representative experiment. Experiments were repeated twice. Asterisks indicate statistically significant differences in viability 
on day 5 (*p < 0.05; ***p < 0.001) as determined using a Student’s t test. EZH2, enhancer of zeste homolog 2; shEZH2, short 
hairpin enhancer of zeste homolog 2; SCLC, small-cell lung cancer; OD, optical density.
FIGURE 3.  Apoptotic rates are elevated on EZH2 inhibition. Levels of apoptosis for EZH2 knockdown and control small-cell 
lung cancer cells were obtained by flow cytometry after ethanol fixation and propidium iodide incorporation. Cells in the sub-
G0/1 phase (characterized by low DNA content because of loss of fragmented DNA caused by ethanol permeabilization), which 
were also within the gate for viable cells (forward vs. side scatter dot plot) were considered apoptotic. Results plotted are mean 
+ standard deviation of the percentage of viable cells that were apoptotic from three independent experiments. Student’s t tests 
were used to compare EZH2 knockdown cells with respective PLKO controls. Asterisks indicate statistically significant differences 
(*p < 0.05; ***p < 0.001). EZH2, enhancer of zeste homolog 2; shEZH2, short hairpin enhancer of zeste homolog 2.
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effect of EZH2 on cell viability and apoptosis, specifically in 
SCLC. It is noteworthy that E2F factors such as E2F1 may 
drive contradictory effects in different human cancers, promot-
ing either proliferation or tumor suppression.8 Considering the 
opposing cell responses that E2F overactivation can induce in 
different cell contexts, it seems that activation of EZH2, which 
results from E2F disruption, manifests the oncogenic role of 
E2F in SCLC.
Of note, Wu et al.9 also demonstrated EZH2 was a potent 
inhibitor of apoptosis in E2F-associated transformation in dif-
ferent cancer types, although not in SCLC. However, mecha-
nistic subtype differences are apparent; in NSCLC, EZH2 
exerts its antiapoptosis function through Bim repression, 
whereas we showed it inhibits Puma and Bad in SCLC. In 
addition to its effects on apoptosis, our results showed EZH2 
knockdown led to increased p21 expression, which is another 
mechanism through which EZH2 may enhance the ability of 
SCLC to escape cell-cycle regulation. The regulation of p21 
expression by EZH2 could be because of the fact that EZH2 
is known to play a role in down-regulation of runt-related 
transcription factor 3 (RUNX3), a transactivator of p21, via 
H3K27 trimethylation in the promoter region.10
Additionally, it is noteworthy that transcription of EZH2 
can be repressed by p53 on p21-mediated inactivation of the 
RB/E2F pathway.11 A correlation analysis between mRNA 
expression of p21 and EZH2 in cell lines with wild-type TP53 
revealed a strong negative correlation (r = −0.92962) sup-
porting the relationship between these two gene expressions, 
whereas the correlation analysis in mutated cell lines did not 
reveal a significant relationship. Establishment of a nonmalig-
nant neuroendocrine cell model would be required to better 
characterize the cell-type–specific interplay between EZH2 
and p21 in future studies. Taken together, our results in SCLC 
and those from other cancer types suggest EZH2 drives the 
malignant phenotype of SCLC through inhibition of apoptosis 
and cell-cycle inhibitors (Fig. 4).
EZH2 as a Clinical Biomarker and 
Therapeutic Target in SCLC
The utility of EZH2 as a clinical marker is currently 
being explored in a variety of human cancers, and expression 
of EZH2 has recently been correlated with lung cancer sub-
type and metastasis.12 Additionally, EZH2 overexpression has 
been shown to contribute to acquired cisplatin resistance in 
ovarian cancer cells.13 On the basis of these findings, there 
is great potential for EZH2 expression levels to serve as a 
predictor of drug resistance and clinical outcome in SCLC. 
Additionally, the biological significance of EZH2 in SCLC 
highlights its potential as a therapeutic target. Inhibition of 
EZH2 has shown promising results in lymphoma cells14 and 
it synergizes with histone deacetylase (HDAC) inhibition in 
mice implanted with human acute myeloid leukemia.15 In 
fact, EZH2-mediated gene silencing was shown to be depen-
dent on HDAC activity.16 Thus, combined inhibition of EZH2 
and HDAC could generate a synergistic effect on SCLCs 
because they are highly sensitive to epigenetic modulators.7,17 
Considering the dependence of SCLC on EZH2, patients could 
potentially benefit greatly from EZH2 targeting. This could be 
achieved by targeting the Polycomb repressor complex 2, for 
example, using the S-adenosylhomocysteine hydrolase inhibi-
tor 3-deazaneplanocin A, or using more EZH2-specific inhibi-
tors such as that described by Knutson et al.12 HDAC inhibitors 
(such as Valproate), which interfere with the Polycomb repres-
sor complex 2 complex to cause global changes in chromatin 
modifications, should also be considered, especially in combi-
nation with these therapies.
The RB1/E2F pathway is disrupted in over 90% of 
SCLCs. Activation of the oncogene EZH2 is a major con-
sequence of RB1/E2F pathway deregulation, and EZH2 
expression has a significant effect on SCLC viability. We 
demonstrated for the first time that EZH2 promotes the cell 
cycle and inhibits apoptosis in SCLC, favoring the oncogenic 
FIGURE 4.  The postulated role of EZH2 in SCLC biology. The 
RB1/E2F pathway is disrupted in the vast majority of SCLCs 
through RB1 inactivation or E2F copy number gains. The 
model illustrated summarizes the different activities of E2F 
factors that have been described in cancer and the particular 
role of EZH2 that we have discovered in SCLC (circled). Besides 
activation of the usual cell-cycle factors required for cell-cycle 
progression, such as cyclins A and E; p107; dihydrofolate 
reductase; thymidine kinase; thymidylate synthetase; PCNA; or 
DNA polymerase α, E2F overactivation can also lead to inhibi-
tion of the cell cycle in specific scenarios through induction 
of p21 and activation of apoptosis. EZH2 plays an essential 
role in SCLC by favoring the oncogenic processes of the RB1/
E2F pathway in SCLC. Specifically, EZH2 negatively regulates 
the expression of the proapoptotic factors, Puma and Bad, as 
well as the cell-cycle inhibitor, p21, thereby promoting SCLC 
tumorigenicity. Given the functions of EZH2 in SCLC biology, 
our findings suggest that it is a promising therapeutic target for 
this cancer type. EZH2, enhancer of zeste homolog 2; RB1, reti-
noblastoma protein; SCLC; small-cell lung cancer; PCNA, pro-
liferating cell nuclear antigen; DHFR, dihydroolate reductase; 
CDK, cyclin-dependent kinases; TS, thymidylate synthetase.
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processes of the RB1/E2F pathway. Furthermore, based on the 
comparison of our work in SCLC and the works of others in 
different cancer types, EZH2 seems to regulate various apop-
totic factors in a cancer-specific manner. This work further 
confirms the oncogenic role of EZH2 in SCLC and empha-
sizes the great opportunity and promise for the development 
of novel therapeutic agents that target EZH2 for the treatment 
of this aggressive cancer.
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Erratum
Impact of PET Staging in Limited-Stage Small-Cell Lung Cancer: Erratum
One of the articles cited by the authors in the article that appeared on page 899 of the July issue of the Journal of Thoracic Oncology was not included in the 
reference list. The study by Lee et al. cited at the end of page 899 should have appeared in the reference list as follows:
Lee JW, Lee SM, Lee HS, et al. Comparison of diagnostic ability between (99m)Tc-MDP bone scan and (18)F-FDG PET/CT for bone metastasis in patients 
with small cell lung cancer. Ann Nucl Med. 2012;26:627–633.
Reference:
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Lin LL, Simone CB, Apisarnthanarax S, Rengan R. Impact of PET staging in limited-stage small-cell lung cancer. J Thorac Oncol. 2013;8:889–905.
